Centrum Medyczne ENEL-MED SA (ENE) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Centrum Medyczne ENEL-MED SA stock PLN 10.03, price PLN 19.30, that is 48.0% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 13.10 PLN – 27.60 PLN · fair‑value band 7.52 PLN – 12.68 PLN · the 19.30 PLN price screens above the 10.03 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow Centrum Medyczne ENEL-MED in your weekly email
Every Wednesday you see whether Centrum Medyczne ENEL-MED is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Centrum Medyczne ENEL-MED S.A., together with its subsidiaries, operates hospitals in Poland, Austria, France, the United Kingdom, and internationally.
Show moreShow less
It offers various medical services comprising pediatric specialist consultations, dentistry, orthopedic, infertility treatment, rehabilitation, psychological, imaging and diagnostics, laboratory diagnostics, and emergency care services.
The company also provides vaccination services for adult and children. Centrum Medyczne ENEL-MED S.A. was founded in 1993 and is headquartered in Warsaw, Poland.
Stock analysis
Centrum Medyczne ENEL-MED SA (ENE) currently trades at 19.30 PLN, while our model-based Fair Value estimate is 10.03 PLN, 48% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 16.01 PLN per share, and 3 of the 23 models we run sit above the 19.30 PLN price.
Bear case: the Asset-Based group reads lowest at 3.91 PLN, and 20 of the 23 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 7.52 PLN (bear) to 12.68 PLN (bull), the price of 19.30 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Centrum Medyczne ENEL-MED SA reported revenue of 854M PLN in FY2025 versus 441M PLN in FY2021, a compound +18.0%/yr. Reported net income was 12.9M PLN in FY2025.
Key figures
Market cap 546M PLN (≈ $139M) Micro · P/E ratio 32.2 · P/S ratio 0.59 · EPS (TTM) 0.6000 PLN · Net margin 1.8% · Return on equity 9.1% · Return on assets (EBIT) 1.1% (5-year average) · Operating margin 4.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −48%, ENE screens richer than that median.
Fair Value models
Bear7.52 PLNFair Value 10.03 PLNBull12.68 PLN
Price 19.30 PLN · Downside -48.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.5145 PLN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+16.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.4%
Start year 2020 (pandemic). Over 10 years: +13.8% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+16.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+16.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 3%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Poland: IMF forecast 3.1% a year to 2030, 4.6% from 2016 to 2025) that is about +15.5% a year for the price.
Compare Centrum Medyczne ENEL-MED SA with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−48.0% · Bottom 25%
Profitability
Return on equity (12 months)9.1% · Above median
Return on assets2.0% · Below median
Net margin (12 months)1.8% · Below median
Operating margin (12 months)4.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)16.7% · Top 25%
Balance sheet
Debt / equity0.09× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)32.2× · Pricier than median
P/B2.94× · Pricier than median
P/S (12 months)0.59× · Cheapest 25%
Price / free cash flow (fiscal year)25.0× · Pricier than median
EV/EBITDA10.6× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 34
FUTURE (revenue growth)84· sector 31
PAST (return on equity)36· sector 32
HEALTH (low debt)95· sector 90
DIVIDEND (yield)0· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Centrum Medyczne ENEL-MED SA Fair Value". https://www.fairvalue-calculator.com/stock/ENE
Frequently asked questions
Is Centrum Medyczne ENEL-MED SA (ENE) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 10.03 PLN versus a price of 19.30 PLN, about 48% lower (overvalued).
What is the fair value of ENE?
Our model-based fair value for Centrum Medyczne ENEL-MED SA is 10.03 PLN (as of Nov 7, 2026), built from audited fundamentals. The current price: 19.30 PLN.
What is the quality score of ENE?
Centrum Medyczne ENEL-MED SA has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Centrum Medyczne ENEL-MED SA (ENE)?
Our model-based price target is the fair value of 10.03 PLN (as of Nov 7, 2026) from 24 valuation models. Cautious scenario 7.52 PLN, optimistic scenario 12.68 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Centrum Medyczne ENEL-MED SA stock forecast for 2026?
Our models put fair value at 10.03 PLN, about 48% lower versus a price of 19.30 PLN (overvalued). Cautious scenario 7.52 PLN, optimistic scenario 12.68 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Centrum Medyczne ENEL-MED SA (ENE)?
Centrum Medyczne ENEL-MED SA reported trailing-twelve-month revenue of about 920M PLN (latest available figure, as of Nov 7, 2026).
What growth is priced into Centrum Medyczne ENEL-MED SA (ENE)?
For today's price to be fair in a discounted-cash-flow model, Centrum Medyczne ENEL-MED SA would have to grow free cash flow by +19.2 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.4 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of ENE use?
Our models discount Centrum Medyczne ENEL-MED SA at 12.1 %: a base by market capitalisation (micro), damped by beta 0.15, country premium for Poland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Centrum Medyczne ENEL-MED SA that is +19.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Centrum Medyczne ENEL-MED SA (ENE) delivered so far?
Over the past 5 years revenue at Centrum Medyczne ENEL-MED SA grew +16.4 % a year. The price currently implies free-cash-flow growth of +19.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Centrum Medyczne ENEL-MED SA (ENE) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Centrum Medyczne ENEL-MED SA (+19.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Centrum Medyczne ENEL-MED SA (ENE)?
The free-cash-flow yield on the price is 3.99 %: that much free cash flow Centrum Medyczne ENEL-MED SA produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Centrum Medyczne ENEL-MED SA (ENE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Centrum Medyczne ENEL-MED SA it is 10.03 PLN per share (as of Nov 7, 2026), against a price of 19.30 PLN. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Centrum Medyczne ENEL-MED SA stock overvalued or undervalued in 2026?
As of Nov 7, 2026, ENE trades above its calculated fair value: price 19.30 PLN, fair value 10.03 PLN, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ENE?
No. The price is what the market pays today (19.30 PLN); the fair value is what the company's own numbers justify (10.03 PLN). For Centrum Medyczne ENEL-MED SA the two are 9.27 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Centrum Medyczne ENEL-MED SA worth?
The market values Centrum Medyczne ENEL-MED SA at about 546M PLN (market capitalisation, as of Nov 7, 2026). Per share that is 19.30 PLN; our models calculate a fair value of 10.03 PLN per share.
What do the bullish and bearish scenarios say about ENE?
Our models span a range for Centrum Medyczne ENEL-MED SA: cautious scenario 7.52 PLN, base 10.03 PLN, optimistic 12.68 PLN per share (as of Nov 7, 2026, price 19.30 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ENE?
Centrum Medyczne ENEL-MED SA trades at a price-to-earnings ratio of 32.2 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 10.03 PLN is built from several models across several years. Other multiples: P/B 2.9, P/S 0.6, EV/EBITDA 10.6.
How solid is the balance sheet of Centrum Medyczne ENEL-MED SA (ENE)?
Balance-sheet figures for Centrum Medyczne ENEL-MED SA (as of Nov 7, 2026): return on equity 9.1%, debt of 0.09 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is ENE from its 52-week high?
Centrum Medyczne ENEL-MED SA trades at 19.30 PLN, about 29% below its 52-week high of 27.20 PLN and 12% above the low of 17.20 PLN (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 10.03 PLN is for.
Which stocks are comparable to Centrum Medyczne ENEL-MED SA?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Centrum Medyczne ENEL-MED SA stock attractive at the current price?
The data as of Nov 7, 2026: price 19.30 PLN, calculated fair value 10.03 PLN (−48%), Quality Score 50/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ENE calculated?
We run Centrum Medyczne ENEL-MED SA through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 10.03 PLN builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Centrum Medyczne ENEL-MED SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Centrum Medyczne ENEL-MED SA (ENE)?
The closing price on Nov 6, 2026 was 19.30 PLN. Our model-based fair value is 10.03 PLN, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Centrum Medyczne ENEL-MED SA right now?
The price sits above even our optimistic bull case (12.68 PLN). The favourable scenario is already priced in. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Centrum Medyczne ENEL-MED SA (ENE) come from?
Earnings per share at Centrum Medyczne ENEL-MED SA grew −4.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.0 %, EBIT margin −10.4 %, tax rate −2.0 %, residual (interest, one-offs) −1.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Centrum Medyczne ENEL-MED SA
How large is the market capitalisation of Centrum Medyczne ENEL-MED SA (ENE)?
The market capitalisation of Centrum Medyczne ENEL-MED SA is 546M PLN (≈ $139M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Centrum Medyczne ENEL-MED SA (ENE)?
The price-to-sales ratio of Centrum Medyczne ENEL-MED SA is 0.59 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Centrum Medyczne ENEL-MED SA (ENE)?
Earnings per share at Centrum Medyczne ENEL-MED SA are 0.6000 PLN (price ÷ EPS = P/E 32.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Centrum Medyczne ENEL-MED SA (ENE)?
The net margin of Centrum Medyczne ENEL-MED SA is 1.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Centrum Medyczne ENEL-MED SA (ENE)?
The return on equity (ROE) of Centrum Medyczne ENEL-MED SA is 9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Centrum Medyczne ENEL-MED SA (ENE)?
On an EBIT basis the return on assets of Centrum Medyczne ENEL-MED SA is 1.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Centrum Medyczne ENEL-MED SA (ENE)?
The operating margin of Centrum Medyczne ENEL-MED SA is 4.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Centrum Medyczne ENEL-MED SA (ENE)?
Revenue at Centrum Medyczne ENEL-MED SA is growing +16.7% versus a year earlier (3y avg +20.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Centrum Medyczne ENEL-MED SA (ENE)?
Earnings per share at Centrum Medyczne ENEL-MED SA are growing −86.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Centrum Medyczne ENEL-MED SA (ENE) carry?
The net debt of Centrum Medyczne ENEL-MED SA is 308M PLN (fiscal year 2025, ≈ 14.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Centrum Medyczne ENEL-MED SA in the live analysis
One click puts Centrum Medyczne ENEL-MED SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026